Penpulimab vs Retifanlimab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: PD-1 · full Non-Small Cell Lung Cancer pipeline
Penpulimab
Marketed by Akeso and partners
NCT03866993 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled Phase 3 trial in 350 patients with advanced squamous non-small-cell lung cancer, all of whom also received paclitaxel and carboplatin. An independent radiology committee assessed progression-free survival in two primary populations: all randomized patients and the PD-L1-positive subgroup. Penpulimab improved progression-free survival in both populations (median 7.6 vs 4.2 months overall and 8.1 vs 4.2 months in PD-L1-positive patients, both p<0.0001), so the trial met its primary endpoint. The figures come from the peer-reviewed Lancet Respiratory Medicine paper.
Reported efficacy
Progression-free survival (PFS) in intent-to-treat (ITT) population, assessed by Independent Radiologist Review Committee(IRRC) in accordance with RECIST v1.1 (Up to approximately 2 years); PFS in PD-L1-selected population, assessed by IRRC in accordance with RECIST v1.1 (Up to approximately 2 years): Primary 1, IRRC-assessed PFS in the ITT population (final analysis): median 7.6 months (95% CI 6.8 to 9.6) penpulimab + chemotherapy vs 4.2 months (95% CI 4.2 to 4.3) placebo + chemotherapy; HR 0.43 (95% CI 0.33 to 0.56); p<0.0001, met. Primary 2, IRRC-assessed PFS in the PD-L1-positive subgroup: median 8.1 vs 4.2 months; HR 0.37 (95% CI 0.27 to 0.52); p<0.0001, met. (met)
Result source: NCT03866993
Retifanlimab
Marketed by Incyte
NCT04205812 · Phase 3 · completed
Participants were randomly assigned and double-blinded to receive retifanlimab or placebo with standard chemotherapy, with 391 in the retifanlimab group and 192 in the control group. The hard clinical primary endpoint of overall survival was met, favoring retifanlimab (hazard ratio 0.75; p=0.0042).
Next expected readout: December 2027 · NCT07219576 (registry estimate)
Reported efficacy
Overall Survival (up to 39.1 months): Overall Survival (up to 39.1 months): Retifanlimab + Chemotherapy 18.1 months (95% CI 16.2 to 21) vs Placebo + Chemotherapy 13.4 months (95% CI 11 to 16.7) (met)
Result source: NCT04205812
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Penpulimab | Retifanlimab |
|---|---|---|
| PFS, median | 8.6 vs 4.2a+4.4 vs placeboNCT03866993 | 7.7 vs 5.5+2.2 vs placeboNCT04205812 |
| OS, median | —Not posted · NCT03866993 | 18.1 vs 13.4+4.7 vs placeboNCT04205812 |
| ORR | —Not posted · NCT03866993 | 51.7% vs 38.5%+13.2 vs placeboNCT04205812 |
| Duration of response, median | —Not posted · NCT03866993 | 12.7 vs 6.1+6.6 vs placeboNCT04205812 |
PFS, median
- Penpulimab
- 8.6 vs 4.2a+4.4 vs placeboNCT03866993
- Retifanlimab
- 7.7 vs 5.5+2.2 vs placeboNCT04205812
OS, median
- Penpulimab
- —Not posted · NCT03866993
- Retifanlimab
- 18.1 vs 13.4+4.7 vs placeboNCT04205812
ORR
- Penpulimab
- —Not posted · NCT03866993
- Retifanlimab
- 51.7% vs 38.5%+13.2 vs placeboNCT04205812
Duration of response, median
- Penpulimab
- —Not posted · NCT03866993
- Retifanlimab
- 12.7 vs 6.1+6.6 vs placeboNCT04205812
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Penpulimab: 0 of 4 rows · Retifanlimab: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Penpulimab | Retifanlimab |
|---|---|---|
| Dropout rate | — | 100%Retifanlimab + Chemotherapy NCT04205812 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 show 1 more result—Retifanlimab Monotherapy NCT04205812 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 |
| Discontinued due to AEs | — | —Retifanlimab + Chemotherapy NCT04205812 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 show 1 more result—Retifanlimab Monotherapy NCT04205812 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 |
| Serious AEs | — | 40.6%Retifanlimab + Chemotherapy NCT04205812 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 show 1 more result20.3%Retifanlimab Monotherapy NCT04205812 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 |
| Most frequent reported AEs | — | anaemia 60.4% (placebo 56.8%) decreased appetite 22.6% (placebo 13.2%) neutrophil count decreased 21.6% (placebo 17.4%) NCT04205812 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 show 1 more resultaspartate aminotransferase increased 23.7% (placebo 22.1%) anaemia 22% (placebo 56.8%) alanine aminotransferase increased 15.3% (placebo 23.7%) NCT04205812 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 |
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Retifanlimab
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Penpulimab's landscape · Retifanlimab's landscape